title: Two versus three doses of a meningococcal C conjugate vaccine concomitantly administered with a hexavalent DTaP-IPV-HBV/Hib vaccine in healthy infants.
abstract: The immunogenicity and reactogenicity of a meningococcal serogroup C (MenC) conjugate vaccine given concomitantly with DTaP-IPV-HBV/Hib vaccine according to a two- or three-dose schedule in healthy infants was evaluated. At 1 month post-vaccination, 98% (two doses) and 100% (three doses) of subjects had serum bactericidal antibody using human complement assay (hSBA) titres > or =1:8; at 12 months of age > or =89% of subjects in each group remained seroprotected. Induction of immunological memory, as evaluated by administration of a meningococcal serogroup A/C polysaccharide vaccine challenge dose, was similar for both regimens and no interference was observed in the immune response to MenC or hepatitis B virus antigens. Reactogenicity was similar in each group. MenC conjugate vaccine given concomitantly with DTaP-IPV-HBV/Hib to healthy infants in the first year of life using a two-dose schedule is as safe and immunogenic as a three-dose regimen.
authors.affiliation: Zentrum für Präventive Pädiatrie, Kinderklinik, Johannes Gutenberg-Universität Mainz, Langenbeckstrabe 1, 55131 Mainz, Germany. joe.schmitt@novartis.com
authors.forename: Heinz-J
authors.initials: HJ
authors.lastname: Schmitt
authors.forename: Katrin Simone
authors.initials: KS
authors.lastname: Steul
authors.forename: Astrid
authors.initials: A
authors.lastname: Borkowski
authors.forename: Francesca
authors.initials: F
authors.lastname: Ceddia
authors.forename: Ellen
authors.initials: E
authors.lastname: Ypma
authors.forename: Markus
authors.initials: M
authors.lastname: Knuf
mesh_terms: D000907:Antibodies, Bacterial / Q000097:blood; D016667:Bacterial Capsules; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D005260:Female; D018073:Haemophilus Vaccines; D006510:Hepatitis B Antibodies / Q000097:blood; D017325:Hepatitis B Vaccines; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D007156:Immunologic Memory; D007223:Infant; D008297:Male; D008585:Meningitis, Meningococcal / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D050296:Microbial Viability; D011054:Poliovirus Vaccine, Inactivated; D017778:Vaccines, Combined / Q000008:administration & dosage* / Q000009:adverse effects*; D018074:Vaccines, Conjugate / Q000008:administration & dosage* / Q000009:adverse effects*
chemical_list: D000907:Antibodies, Bacterial; C451839:DTPa-HBV-IPV combined vaccine; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D018073:Haemophilus Vaccines; C044237:Haemophilus influenzae type b polysaccharide vaccine; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D022401:Meningococcal Vaccines; D011054:Poliovirus Vaccine, Inactivated; D017778:Vaccines, Combined; D018074:Vaccines, Conjugate; C410218:serogroup C meningococcal conjugate vaccine